Fort Point Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$596K Buy
1,259
+666
+112% +$295K 0.04% 155
2026
Q1
$265K Buy
593
+27
+5% +$12.6K 0.03% 193
2025
Q4
$248K Sell
566
-21
-4% -$9.05K 0.03% 212
2025
Q3
$230K Sell
587
-121
-17% -$50.6K 0.03% 201
2025
Q2
$315K Buy
708
+34
+5% +$15.7K 0.02% 275
2025
Q1
$327K Sell
674
-146
-18% -$68K 0.04% 260
2024
Q4
$330K Buy
820
+132
+19% +$61.2K 0.04% 252
2024
Q3
$320K Buy
688
+158
+30% +$75.9K 0.04% 234
2024
Q2
$248K Sell
530
-15
-3% -$6.51K 0.03% 276
2024
Q1
$228K Hold
545
0.03% 295
2023
Q4
$222K Buy
+545
New +$201K 0.03% 270

Other funds holding VRTX

Fort Point Capital Partners's VRTX Position: Q2 2026 in Review

Fort Point Capital Partners increased its Vertex Pharmaceuticals (VRTX) stake by 112% in Q2 2026, buying an estimated $295K and bringing the position to 1,259 shares worth $596K. The position accounts for 0.04% of the portfolio, ranked #155.

Fort Point Capital Partners first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Fort Point Capital Partners held 1,259 shares of Vertex Pharmaceuticals worth $596K as of Q2 2026.
  • Fort Point Capital Partners bought 666 Vertex Pharmaceuticals shares in Q2 2026, an estimated $295K.
  • Vertex Pharmaceuticals made up 0.04% of Fort Point Capital Partners's portfolio in Q2 2026, its #155 holding.
  • Fort Point Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Fort Point Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.